Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.

Falcone GJ, Brouwers HB, Rosand J.

Stroke. 2012 Dec;43(12):3158-9. doi: 10.1161/STROKEAHA.112.676932. Epub 2012 Nov 15. No abstract available.

2.

Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.

Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele B.

Stroke. 2012 Dec;43(12):3189-95. doi: 10.1161/STROKEAHA.112.670604. Epub 2012 Nov 15.

3.

Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.

Capodanno D, Bhatt DL, Goto S, O'Donoghue ML, Moliterno DJ, Tamburino C, Angiolillo DJ.

J Thromb Haemost. 2012 Oct;10(10):2006-15. doi: 10.1111/j.1538-7836.2012.04869.x.

4.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.

5.

PAR-1 antagonists: current state of evidence.

Chatterjee S, Sharma A, Mukherjee D.

J Thromb Thrombolysis. 2013 Jan;35(1):1-9. doi: 10.1007/s11239-012-0752-4. Review.

PMID:
22644721
6.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators.

N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.

7.

Efficacy and safety of vorapaxar in patients with prior ischemic stroke.

Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E; Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators.

Stroke. 2013 Mar;44(3):691-8. doi: 10.1161/STROKEAHA.111.000433. Epub 2013 Feb 8.

8.

Mechanism of action and clinical development of platelet thrombin receptor antagonists.

Ueno M, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2010 Aug;8(8):1191-200. doi: 10.1586/erc.10.49. Review.

PMID:
20670195
9.

PARtitioning protease signaling.

Nieman MT.

Blood. 2015 Mar 19;125(12):1853-5. doi: 10.1182/blood-2015-01-623835.

10.

Protease-activated receptor-1 antagonists: focus on SCH 530348.

Sugunaraj JP, Mehta V, Kalra A, Sukhija R, Palaniswamy C.

Am J Ther. 2012 Nov;19(6):465-9. doi: 10.1097/MJT.0b013e3181ff7c16. Review.

PMID:
21248619
11.
12.

Vorapaxar: a novel protease-activated receptor-1 inhibitor.

Gurbel PA, Jeong YH, Tantry US.

Expert Opin Investig Drugs. 2011 Oct;20(10):1445-53. doi: 10.1517/13543784.2011.606809. Epub 2011 Aug 6. Review.

PMID:
21819272
13.

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Cho JR, Rollini F, Franchi F, Ferrante E, Angiolillo DJ.

Vasc Health Risk Manag. 2014 Apr 3;10:177-88. doi: 10.2147/VHRM.S36045. eCollection 2014. Review.

14.

Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.

Moschonas IC, Goudevenos JA, Tselepis AD.

Int J Cardiol. 2015 Apr 15;185:9-18. doi: 10.1016/j.ijcard.2015.03.049. Epub 2015 Mar 4. Review.

PMID:
25777282
15.

Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!

Bhandari B, Mehta B.

Recent Adv Cardiovasc Drug Discov. 2014;9(2):73-7. Review.

PMID:
26104312
16.

Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.

Baker NC, Lipinski MJ, Lhermusier T, Waksman R.

Circulation. 2014 Oct 7;130(15):1287-94. doi: 10.1161/CIRCULATIONAHA.114.011471. No abstract available.

17.

Vorapaxar in atherosclerotic disease management.

Cheng JW, Colucci V, Howard PA, Nappi JM, Spinler SA.

Ann Pharmacother. 2015 May;49(5):599-606. doi: 10.1177/1060028015571410. Epub 2015 Feb 13. Review.

PMID:
25680760
18.

Intracranial hemorrhage with Aptivu.

[No authors listed]

AIDS Patient Care STDS. 2006 Dec;20(12):889. No abstract available.

PMID:
17216876
20.

Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.

Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA.

Circulation. 2013 Apr 9;127(14):1522-9, 1529e1-6. doi: 10.1161/CIRCULATIONAHA.112.000679. Epub 2013 Mar 15.

Supplemental Content

Support Center